Menu

Anheuser-Busch Won’t Fund Controversial NIH Alcohol Study

The company’s announcement comes weeks after enrollment was suspended.

Jun 11, 2018
Shawna Williams

ISTOCK, DEBRAMILLETUpdate (June 18): STAT News reports that NIH has shut down the alcohol study. Lawrence Tabak, the head of a task force charged with examining the study, says, “the nature of the engagement with industry representatives calls into question the impartiality of the process.”


Anheuser-Busch InBev has withdrawn a $15-million funding commitment for a mammoth National Institutes of Health study on the effects of moderate alcohol consumption, The New York Times reports. The company’s announcement, made on Friday (June 8), comes after the planned study drew scrutiny over potential conflicts of interest on the part of NIH, which had courted corporate sponsors with the prospect of producing evidence of health benefits of regular drinking.


See “NIH Turned Down Investigators Who Provoked Ire From Alcohol Industry


The planned $100-million study, administered by the NIH’s National Institute of Alcohol Abuse and Alcoholism (NIAAA) would assign thousands of participants either to have an alcoholic drink every day or abstain, and track their health outcomes and mortality over six years. The New York Times reported in March that in an effort to get beverage makers to pick up most of the tab, NIAAA scientists met with industry leaders and “gave talks strongly suggesting that the study’s results would endorse moderate drinking as healthy.” STAT News later found that a separate funding request from researchers whose work had drawn criticism from industry had been turned down by NIAAA.


Following the revelations, NIH Director Francis Collins announced that the agency was reviewing the process around funding for the trial and would determine whether it should proceed, and that enrollment had been suspended for the time being, The Washington Post reported last month.


Anheuser-Busch announced its decision to withdraw funding in a letter to the Foundation for the National Institutes of Health. According to the Times, the letter concludes, “Unfortunately, recent questions raised around the study could undermine its lasting credibility, which is why we have decided to end our funding.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.